Selective ROCK2 Inhibitor Chemistry for Solubility and Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases mediated by Rho-associated protein kinase (ROCK), particularly ROCK2, are limited in efficacy and specificity, leading to the need for more effective and selective inhibitors.
Innovation Solution
The development of selective inhibitors of ROCK2, specifically compounds with the formula I or II, which exhibit excellent inhibitory activity and selectivity towards ROCK2, improving physicochemical properties such as solubility and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective ROCK inhibitors are used, then broad disease coverage is achieved, but specificity and efficacy are reduced due to off-target effects
Solution Approach 1:
The patent applies local quality by designing ROCK2-selective inhibitors with specific molecular structures (Formula I and II compounds) that target only the ROCK2 isoform rather than all ROCK isoforms. The inhibitors contain specific substituents (R1-R7 groups) that create selective binding to ROCK2's ATP binding site, achieving high specificity while maintaining therapeutic effectiveness for diseases mediated by ROCK2.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters of the inhibitor structure (substituents at positions R1-R7, heterocyclic rings, stereochemistry) to optimize ROCK2 selectivity. By adjusting these structural parameters, the compounds achieve superior specificity over ROCK1 while maintaining efficacy for ROCK2-mediated diseases.
2Reliability
If existing ROCK inhibitors are used, then disease treatment is achieved, but physicochemical properties such as solubility and bioavailability are insufficient
Solution Approach 1:
The patent applies parameter changes by optimizing the physicochemical properties of the inhibitor compounds through structural modification. The compounds in Formula I and II incorporate specific functional groups and substituents that improve solubility, membrane permeability, and bioavailability while maintaining strong ROCK2 inhibitory activity. This systematic optimization of molecular parameters resolves the contradiction between activity and physicochemical properties.
Data Source
AI summary
The present disclosure relates to inhibitors of Rho-associated protein kinase (ROCK), pharmaceutical compositions comprising the same, and use thereof for the prevention or treatment of a disease mediated by the ROCK. Particularly, the inhibitors of ROCK are selective for the inhibition of ROCK2.